Piramal Pharma Gets EIR from US FDA for Bethlehem Plant

Last edition

Piramal Pharma Gets EIR from US FDA for Bethlehem Plant

Piramal Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its manufacturing facility at Bethlehem, USA.

The EIR report signifies the closure of the inspection and allows Piramal Pharma to go ahead and file for drugs the facility in focus.

The US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Bethlehem facility from September 18-27, 2023.

Read more on:
Piramal Pharma

More news about: industrial talks | Published by Manvi | November - 10 - 2023 | 414

Last news about this category

Aprotec Offers its Customers Turnkey Systems for Customised Applications

Cardiotrack Secures USD 2 Million in Pre-Series A Funding

Lupin Receives Approval from US FDA for Varenicline Tablets

Brenntag Specialties and Zeochem Expand Business Collaboration for Pharma EMEA

Cromatic Closes USD 5.3 Million in Oversubscribed Seed Round to Modernize Life Science R&D Outsourcing

Allcargo Supply Chain Launches State-Of-The Art Chemical Warehouse at Navi Mumbai

Great Place to Work Institute Certifies Thermo Fisher Scientific for Fifth Consecutive Year

Pharma Pro&Pack Expo, analytica Anacon India and India Lab Expo to Showcase Innovations in Pharma Processing Equipment and Laboratory Technology

Glenmark Pharmaceuticals in Process of Recalling 1,200 Bottles of Subpotent Hypertension Drug in USA

LEO Pharma Announces Appointment of Nathalie Daste as new Executive VP- Global People and Corporate Affairs

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy